Scholarlink

Purpose <p>Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [<sup>177</sup>Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [<sup>177</sup>Lu]Lu-PSMA-617 with EBRT and ADT.</p> Methods <p>In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25–35 fractions) and 2–3 years ADT with concurrent [<sup>177</sup>Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168&#xa0;h post-injection.</p> Results <p>Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1–2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71&#xa0;Gy/GBq (interquartile range (IQR) 0.5–2.9) at the 9 GBq; 0.91&#xa0;Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47&#xa0;Gy/GBq (0.3–0.5) at cycle 2.</p> Conclusions <p>Concurrent [<sup>177</sup>Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PROQURE-I: a phase I study adding concurrent [177Lu]Lu-PSMA-617 to EBRT and ADT in curative intent treatment of N1 prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月27日

查看全文
  • Lotte G. Zuur,
  • Denise S. Hoogenkamp,
  • Esmée C. A. van der Sar,
  • Debra van Asten,
  • Marnix G. E. H. Lam,
  • Jochem R.N. van der Voort-van Zyp,
  • Pim J. van Leeuwen,
  • Berlinda J. de Wit - van der Veen,
  • Daphne M. V. de Vries-Huizing,
  • Jeroen J. M. A. Hendrikx,
  • Arthur J. A. T. Braat,
  • Wouter V. Vogel

摘要

Purpose

Current treatment of N1M0 prostate cancer (PCa) with locoregional external beam radiotherapy (EBRT) and long-term androgen deprivation therapy (ADT) has suboptimal five-year recurrence-free rates. Adding [177Lu]Lu-PSMA-617 may improve tumour control and reduce reliance on long-term ADT. This phase-1 dose-escalation study explores the safety and tolerability of adding concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT.

Methods

In the multi-centre phase-1 dose-escalation study (PROQURE-I), treatment-naïve cT1-4N1M0 PCa patients received standard locoregional EBRT (25–35 fractions) and 2–3 years ADT with concurrent [177Lu]Lu-PSMA-617 to determine its maximum tolerated dose (MTD). Dose levels included one cycle (3, 6 or 9 GBq in week 2 of EBRT) or two cycles (2 × 7.4 GBq in week 2 and 4). Grade ≥ 3 toxicity (CTCAE v5.0) was dose-limiting. Tumour and organ dosimetry was performed with SPECT/CT and planar imaging at 4, 24 and 168 h post-injection.

Results

Fourteen patients were included. No dose-limiting toxicity was observed and the MTD was not reached. Reported grade 1–2 toxicities were related to EBRT. Median absorbed dose to the primary tumour of 0.71 Gy/GBq (interquartile range (IQR) 0.5–2.9) at the 9 GBq; 0.91 Gy/GBq (IQR 0.6-1.0) at 7.4 GBq cycle 1; and 0.47 Gy/GBq (0.3–0.5) at cycle 2.

Conclusions

Concurrent [177Lu]Lu-PSMA-617 with EBRT and ADT is safe and well tolerated in treatment-naïve N1M0 PCa. Clinical efficacy should be evaluated in a subsequent phase 2 study.